Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer
JF Lu, SM Eppler, J Wolf, M Hamilton… - Clinical …, 2006 - Wiley Online Library
Objective Our objective was to assess the pharmacokinetics of erlotinib in a large patient
population with solid tumors, identify covariates, and explore relationships between …
population with solid tumors, identify covariates, and explore relationships between …
Effects of smoking on the pharmacokinetics of erlotinib
M Hamilton, JL Wolf, J Rusk, SE Beard, GM Clark… - Clinical Cancer …, 2006 - AACR
Purpose: To compare the pharmacokinetic variables of erlotinib in current smokers with
nonsmokers after receiving a single oral 150 or 300 mg dose of erlotinib. Experimental …
nonsmokers after receiving a single oral 150 or 300 mg dose of erlotinib. Experimental …
[HTML][HTML] A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR. 21
Introduction BR. 21 demonstrated significant survival benefit for non-small cell lung cancer
patients receiving erlotinib compared with placebo. We undertook to characterize, by …
patients receiving erlotinib compared with placebo. We undertook to characterize, by …
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese …
M Fukudo, Y Ikemi, Y Togashi, K Masago… - Clinical …, 2013 - Springer
Background Erlotinib shows large inter-patient pharmacokinetic variability, but the impact of
early drug exposure and genetic variations on the clinical outcomes of erlotinib remains fully …
early drug exposure and genetic variations on the clinical outcomes of erlotinib remains fully …
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers
AN Hughes, MER O'Brien, WJ Petty… - Journal of clinical …, 2009 - ascopubs.org
Purpose Cigarette smoking induces CYP1A1/1A2 and is hypothesized to alter erlotinib
pharmacokinetics. This study aimed to determine the maximum tolerated dose (MTD) of …
pharmacokinetics. This study aimed to determine the maximum tolerated dose (MTD) of …
A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer
DT Milton, CG Azzoli, RT Heelan… - … Journal of the …, 2006 - Wiley Online Library
BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with …
N Yamamoto, A Horiike, Y Fujisaka… - Cancer chemotherapy …, 2008 - Springer
Purpose The objectives of this phase I dose-finding study of erlotinib were to investigate the
toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess …
toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess …
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva)
M Hidalgo, D Bloedow - Seminars in oncology, 2003 - Elsevier
Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
A phase II pharmacodynamic study of erlotinib in patients with advanced non–small cell lung cancer previously treated with platinum-based chemotherapy
E Felip, F Rojo, M Reck, A Heller, B Klughammer… - Clinical Cancer …, 2008 - AACR
Purpose: To examine potential markers of clinical benefit and the effects of erlotinib on the
epidermal growth factor receptor (EGFR) signaling pathway in advanced non–small cell …
epidermal growth factor receptor (EGFR) signaling pathway in advanced non–small cell …
Determinants of tumor response and survival with erlotinib in patients with non—small-cell lung cancer
R Pérez-Soler, A Chachoua, LA Hammond… - Journal of clinical …, 2004 - ascopubs.org
Purpose Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR)
tyrosine kinase inhibitor. This phase II study of erlotinib in patients with HER1/EGFR …
tyrosine kinase inhibitor. This phase II study of erlotinib in patients with HER1/EGFR …
相关搜索
- small cell lung cancer
- nonsmall cell lung cancer
- lung cancer erlotinib in patients
- solid tumors erlotinib in patients
- clinical pharmacokinetics erlotinib in patients
- solid tumors safety relationship
- safety relationship erlotinib in patients
- clinical pharmacokinetics safety relationship
- solid tumors clinical pharmacokinetics
- lung cancer survival with erlotinib
- lung cancer tumor response
- solid tumors dose finding
- japanese patients population pharmacokinetics
- drug concentrations population pharmacokinetics
- pharmacogenomic analysis population pharmacokinetics
- cerebrospinal fluid population pharmacokinetics